About the Undruggables Portfolio
The Targeting the Undrugged series is focused on developing new drug modalities to target ‘undruggable’ pathways. Recent technological advancements in structural analysis, including techniques such as cryo-electron microscopy and XFEL together with a deeper understanding of the human genome has opened new drug targets for the pharmaceutical industry to investigate. These targets include protein degradation pathways (including ubiquitin and E3 ligases), K-Ras, transcription factors, Amyloid Beta, RNA and even the proteasome.
With significant investment and collaborations increasing rapidly across the undruggable space, no wonder there is a lot of excitement. The community is watching closely, awaiting critical updates for topics as diverse as the first PROTAC clinical trials, drug discovery to target misfolded proteins, epitranscriptomics, platforms for RNA and early results for the first C-Myc modulators. Crucially, everybody is looking out for the next undruggable target. The meetings in the Targeting the Undrugged series will allow you to connect with expert academics, innovative biotechs and leading industry at the translational level. You'll get the chance to discuss the innovations and opportunities, and address the key hurdles, that come with developing new drug discovery platforms such as proof of concept parameters, profiling efficacy, bioavailability and toxicology.